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An overactive bladder, characterized by symptoms of increased frequency of micturition, urgency, and urge incontinence, is very common in the geriatric population, a group that is rapidly increasing in number (Bulmer and Abrams, 2000) . Urge urinary incontinence is one of the most common types of incontinence in geriatric patients (Resnick and Yalla, 1985) . Antimuscarinic agents are widely used to treat those with overactive bladders because parasympathetic innervation is the predominant stimulus for bladder contraction (Anderson, 1993; Chapple, 2000) . Propiverine, a benzilic acid derivative ( Fig. 1) , is one of the anticholinergic agents most commonly used for the treatment of patients with an overactive bladder (Halaska et al., 1994; Madersbacher et al., 1999; Stöhrer et al., 1999; Madersbacher and Mürtz, 2001) . In clinical trials, propiverine has proved to be an effective drug for urinary incontinence as a result of detrusor overactivity with a moderate incidence of adverse events. The pharmacological profile of propiverine has been extensively studied. In dogs, propiverine increased maximal bladder volume and had inhibitory effects on acetylcholine-induced periodic contractions of the urinary bladder (Kaneko et al., , 1999 . In rats, maximal bladder volume was significantly increased (Nomura et al., 1989) . Furthermore, propiverine exerted competitive anticholinergic and calcium-antagonistic effects in the isolated urinary bladder of mice, rats, dogs, pigs, and humans (Riotte and Mutschler, 1987; Alloussi et al., 1991; Wada et al., 1995; Kaneko et al., 1999; Wuest et al., 2005 Wuest et al., , 2006 .
It has been shown that propiverine is metabolized to form active metabolites-1-methyl-4-piperidyl diphenylpropoxyacetate N-oxide (M-1) and 1-methyl-4-piperidyl benzilate N-oxide (M-2)-in humans ( Fig. 1) Wengler et al., 1988) . The primary metabolic route from propiverine to its major metabolite, M-1, is mediated by CYP3A4; in addition, CYP2C9 and CYP2C19 may be partly involved in the human metabolism (Tomalik-Scharte et al., 2005) . Measurements of propiverine and its metabolites in plasma of rats and humans after the oral administration of propiverine confirmed the presence of relatively high concentrations of these metabolites Wengler et al., 1988; Yamamoto et al., 1995) . In in vitro and in vivo studies, it was previously shown that these metabolites exerted anticholinergic and calcium antagonistic effects in the urinary bladder of rats and guinea pigs Nomura et al., 1989; Wuest et al., 2005 Wuest et al., , 2006 . Therefore, it has been speculated that these metabolites are partially responsible for the spasmolytic activity in the bladder after the oral administration of propiverine. However, the muscarinic receptor activities of these metabolites in relation to the pharmacokinetics of propiverine have not been directly investigated. The aim of the current study was to elucidate the contribution of N-oxide metabolites to the binding of muscarinic receptors of rats after the oral administration of propiverine in relation to plasma and tissue concentrations of these agents using rats. The bladder corresponds to the organ targeted by antimuscarinic agents, whereas the submaxillary gland is the organ related to dry mouth, a typical side effect of these agents. The bladder expresses a majority of M 2 muscarinic receptor subtype, whereas the contractile response is contingent on activation of the M 3 receptor subtype. The salivary glands, such as the submaxillary gland, contain a majority of M 3 receptor subtypes, and the salivation is contingent on activation of these M 3 receptor subtypes (Ito et al., 2009 ).
Materials and Methods

Materials.
[N-Methyl-3 H]scopolamine methyl chloride ([ 3 H]NMS; 3.03 TBq/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Waltham, MA). Propiverine hydrochloride (propiverine) and its N-oxide metabolites were provided by Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan). All the other chemicals were purchased from commercial sources.
Animals. Male and female Sprague-Dawley rats (Charles River Japan, Kanagawa, Japan) weighing approximately 250 to 350 g were used. They were housed with a 12-h light/dark cycle and fed laboratory food and water ad libitum. The study was conducted in accordance with the guidelines of the Experimental Animal Ethical Committee of the University of Shizuoka.
Administration of Propiverine and Tissue Preparation. For the oral administration of propiverine, male rats were fasted for 16 h and then given propiverine (24.8, 74.3 , and 248 mol/kg) dissolved in distilled water. Control animals received the vehicle alone. At various time points (1-12 h) after the administration, rats were killed by taking the blood from the descending aorta under temporary anesthesia with diethyl ether, and the tissues were perfused with cold saline from the aorta. Then, the bladder and submaxillary gland were dissected, and fat and blood vessels were removed by trimming. The tissue was minced with scissors and homogenized by a Kinematica (Littau-Lucerne, Switzerland) Polytron homogenizer in 19 volumes of ice-cold 30 mM Na ϩ / HEPES buffer, pH 7.5. The homogenates were then centrifuged at 40,000g for 20 min. The resulting pellet was suspended in buffer for the binding assay. In ex vivo experiments, there was a possibility that propiverine and its active metabolites might dissociate in part from the receptor sites during tissue preparation (homogenization and suspension) after drug administration. Yamada et al. (1980) have shown that the dissociation of antagonists from receptor sites at 4°C was extremely slow. Therefore, to minimize the dissociation of propiverine and its metabolites from the receptor sites, all the steps in the preparation were performed at 4°C. In fact, there was no large difference in [
3 H]NMS binding parameters [apparent dissociation constant (K d ) and maximal number of binding sites (B max )] between single washing and double washing of rat bladder homogenates at 4°C, 3 h after the oral administration of propiverine hydrochloride (74.3 mol/kg). Protein concentrations were measured by the method of Lowry et al. (1951) .
For the intravesical instillation of M-2, female rats were anesthetized with pentobarbital (121 mol/kg i.p.) (Oki et al., 2004) . Through a midline incision in the abdomen, the bladder was exposed and emptied of urine by sucking through a syringe connected to a 30-gauge needle. M-2 (0.6 ml of 3 or 30 M/rat) dissolved in physiological saline was instilled into the bladder by injecting it directly through a syringe connected to the needle. M-2 solution was kept in the bladder for 60 min by tying the urethral openings with a thread, after which the bladder was evacuated by taking out the thread. Control animals received physiological saline (0.6 ml) alone. Then the bladder and submaxillary gland were dissected and prepared for [ 3 H]NMS binding assay as described above. Muscarinic Receptor Binding Assay. The binding assay for muscarinic receptors was performed using [
3 H]NMS as described previously (Oki et al., 2004) . The crude membranes (240 g of protein) of rat bladder and submaxillary gland were incubated with different concentrations (0.03-1.5 nM) of [ 3 H]NMS in 30 mM Na ϩ /HEPES buffer, pH 7.5. Incubation was carried out for 60 min at 25°C. The reaction was terminated by rapid filtration (Cell Harvester; Brandel Inc., Gaithersburg, MD) through Whatman (Clifton, NJ) GF/B glass fiber filters, and the filters were then rinsed three times with 3 ml of ice-cold buffer. Tissue-bound radioactivity was extracted from the filters overnight by immersion in scintillation fluid (21 toluene, 11 Triton X-100, 15 g of 2,5-diphenyloxazole, and 0.3 g of 1,4-bis[2-(5-phenyloxazolyl)]benzene), and the radioactivity was determined with a liquid scintillation counter. Specific [
3 H]NMS binding was determined experimentally from the difference between counts in the absence and presence of 1 M atropine. The in vitro inhibition by propiverine and its N-oxide metabolites of specific [ 3 H]NMS (0.47 nM for the bladder, 0.14 nM for the submaxillary gland) binding was examined. All the assays were conducted in duplicate.
Measurement of Plasma and Tissue Concentrations of Propiverine and Its Metabolites. The measurement of plasma concentrations of propiverine and its metabolites was performed in rats after the oral administration of propiverine. In the first experiment, plasma concentrations were determined at oral doses of 24.8, 74.3, and 248 mol/kg with four male rats per time point. Next, plasma and tissue concentrations were simultaneously determined at a dose level of 74.3 mol/kg with six male rats for each time point. After the drug administration, rats were killed by the withdrawal of blood from the descending aorta under anesthesia with diethyl ether. Plasma was isolated from blood by centrifugation. The bladder and submaxillary gland were excised, and their respective masses were approximately 75 mg/rat and 420 mg/rat. These tissues were minced and homogenized with 1 and 2 ml of saline, respectively; therefore, the dilution ratios were approximately 14.5 and 5.8. The tissue homogenate and plasma samples were stored at Ϫ80°C until the analysis. Concentrations of propiverine, M-1, and M-2 in plasma and tissue samples were determined by a high-performance liquid chromatography (HPLC)/tandem mass spectrometric method originally developed by Komoto et al. (2004) . The analytes were extracted with 7 ml of dichloromethane from 0.2 ml of plasma or tissue homogenate in neutral conditions (0.5 ml of 10 mM phosphate buffer, pH 7.0, and 0.025 ml of internal standard solution in methanol). The extract was evaporated to dryness under a stream of nitrogen gas and then reconstituted with the HPLC mobile phase. The analytes were separated by HPLC on a C18 reversed-phase column using methanol/1% acetic acid (50:50 for propiverine and M-1; 35:65 for M-2, isocratic elution) as a mobile phase and detected using positive electrospray ionization in selected reaction moni- dmd.aspetjournals.org toring mode. The calibration curve was drawn using blank plasma samples spiked with known concentrations of the analytes. The concentrations of analytical samples were calculated using stable isotope-labeled compounds, propiverine hydrochloride-d 10 , M-1-d 10 , and M-2-d 10 , as internal standards. Thermo Fisher Scientific (Waltham, MA) TSQ7000 liquid chromatography/ mass spectrometry system equipped with a Waters (Milford, MA) 2690/2695 HPLC system was used in the analysis. The ranges of quantification were 2 to 500 ng/ml, 4 to 1000 ng/ml, and 2 to 500 ng/ml for propiverine, M-1, and M-2, respectively. All the determined concentrations were converted to nanomolars (or micromolars) using the dilution ratio of the tissue samples, as well as a molecular weight of 367.48, 383.48, and 341.40 for propiverine, M-1, and M-2, respectively. The lower limit of quantification for propiverine, M-1, and M-2 in the samples analyzed was 5.4, 10.4, and 5.9 nM, respectively. Data Analysis.
[ 3 H]NMS binding data were subjected to a nonlinear regression analysis using GraphPad Prism (version 4; GraphPad Software Inc., San Diego, CA). The apparent dissociation constant (K d ) and maximal number of binding sites (B max ) for [
3 H]NMS (0.03-1.5 nM) were estimated (Yamada et al., 1980) . The ability of muscarinic receptor antagonists to inhibit specific [ 3 H]NMS binding was estimated from the IC 50 values, which are the molar concentrations of unlabeled drugs necessary to displace 50% of the specific binding of [ 3 H]NMS (determined by log probit analysis). The inhibition constant, K i , was calculated from the equation
The area under the curve (AUC) values for the plasma concentration-time profiles were calculated by the linear trapezoidal method using the mean values at each time point. The data below the lower limit of quantification and at 12 h with 24.8 mol/kg dose level were assumed to be zero to calculate the AUC up to 12 h after administration. The statistical analysis of the data was performed with a one-way analysis of variance, followed by Dunnett's test for multiple comparison. The data were expressed as the mean Ϯ S.E. Statistical significance was accepted at P Ͻ 0.05.
Results
In Vitro Muscarinic Receptor Binding. Propiverine (30 nM-3 M), M-1 (1-100 M), and M-2 (30 nM-3 M) inhibited specific [ 3 H]NMS binding in the rat bladder in a concentration-dependent manner in vitro (Fig. 2) , and the respective K i values were 0.30 Ϯ 0.04, 6.50 Ϯ 0.62, and 0.21 Ϯ 0.01 M (Table 1) . Thus, compared with that for propiverine, the K i value for M-1 in the bladder was 22 times larger, and the K i value for M-2 was similar. Also in the submaxillary gland, a similar tendency was observed, and the K i value for each agent was significantly smaller than that in the bladder. The Hill coefficients for these agents were close to unity.
Effects of Oral Administration of Propiverine on Muscarinic Receptors. The effect of the oral administration of propiverine on specific [
3 H]NMS binding in the rat bladder and submaxillary gland was investigated. The oral doses chosen, 24.8 to 248 mol/kg, were expected to produce significant pharmacological effects based on intravenous doses in reducing urinary bladder contractions in rat cystometry (Nomura et al., 1989) . Three hours after the administration of propiverine at the relatively low dose of 24.8 mol/kg, there was a significant increase (38%) in the K d value for specific [ 3 H]NMS binding in the rat bladder compared with the control value ( 3 H]NMS binding in these tissues after intravesical instillation of M-2 were unaltered. The intravesical instillation of M-2 at the lower dose (0.6 ml of 3 M/rat) had little effect on the binding parameters of [
3 H]NMS in the rat tissues. Plasma Concentrations of Propiverine and Its Metabolites. The oral administration of propiverine at 24.8, 74.3, and 248 mol/kg in rats resulted in a dose-dependent increase in the total plasma concentrations of propiverine, M-1, and M-2, with maximal levels reached at 1 h (Fig. 3) . The plasma concentration of M-2 at higher doses tended to increase more than that observed at the lowest dose, indicating saturation in its elimination pathways. This indicated the saturated elimination of this metabolite at higher doses. It is noteworthy that in the plasma of these rats, much higher concentrations of M-1 and M-2 than propiverine were produced. As shown in Table 4 , there were 3.6 to 5.9 higher total plasma concentrations (maximal plasma concentration: C max at 1 h) of M-1 and M-2 than propiverine at doses of 24.8 to 248 mol/kg. Furthermore, AUC values for the total plasma concentration of M-1 compared with propiverine at 24.8, 74.3, and 248 mol/kg were 2.0, 3.0, and 2.9 times greater, respectively, and those for M-2 were 2.6, 7.5, and 6.6 times greater, respectively (Table 4 ). The elimination of these metabolites generally paralleled that of unchanged propiverine.
The rat serum protein binding of propiverine, M-1, and M-2 was 88.77, 63.30, and 31.65%, respectively (Tsuda et al., 1991) . To consider the relationship between the plasma concentration and bladder muscarinic receptor binding, the plasma protein unbound C max and AUC were calculated by multiplying total concentrations (C max , AUC) by the plasma unbound ratios (0.11, 0.37, and 0.68). There were much higher concentrations (C max ) of unbound N-oxide metabolites than propiverine in rats, as shown by 12.5 to 14.9 and 21.8 to 36.1 times higher concentrations, respectively, of unbound M-1 and M-2 than propiverine in rats 1 h after the administration (24.8 -248 mol/kg) (Table 4) . Likewise, AUC values of plasma concentrations of unbound M-1 and M-2 were 6.7 to 9.8 and 15.7 to 45.6 times greater, respectively, than the value of propiverine.
In addition, we estimated the plasma concentrations of unbound M-1 and M-2 as the concentrations of unbound propiverine equivalents based on the K i values for the inhibition of bladder [ 3 H]NMS binding by each agent (Table 1 ). In fact, the concentrations of unbound propiverine equivalents were calculated with multiplying by 
H]NMS binding in the bladder and submaxillary gland of female rats after the intravesical instillation of M-2
Values are the mean Ϯ S.E. for four or five rats. Rats received intravesical M-2 at the dose of 0.6 ml of 3 and 30 M/rat and were sacrificed 60 min later. (Table 4) . Thus, the unbound concentrations (C max , AUC) of M-2 were shown to comprise more than 90% of the sum of the unbound propiverine equivalents in the plasma of rats given propiverine orally. Tissue Concentrations of Propiverine and Its Metabolites. The tissue concentration profile was determined after the oral administration of propiverine at the dose of 74.3 mol/kg in rats to evaluate the contribution of N-oxide metabolites to the drug's action in the bladder and submaxillary gland. In the bladder, M-2 exhibited a much higher concentration than in plasma, and the tissue/plasma (T/P) ratio ranged between 21.3 and 33.6 ( Fig. 4 ; Table 5 ). The mean C max of M-2 in the bladder reached more than 10 M, whereas that for propiverine and M-1 was less than 1 M. On the other hand, in the submaxillary gland, propiverine exhibited high concentrations greater than 1 M, and the T/P ratios ranged from 17.8 to 24.6 (Table 5 ). The N-oxide metabolites distributed slightly to the submaxillary gland, and their C max values were less than 0.3 M. The elimination of propiverine and its metabolites from this organ generally paralleled that from plasma, suggesting no anomalous accumulation of these compounds.
Discussion
The contribution of N-oxide metabolites (M-1, M-2) to the binding of muscarinic receptors in the bladder was investigated by measuring muscarinic receptor binding and concentrations of propiverine and its metabolites in the plasma and tissues of rats after oral administration of propiverine. Propiverine, M-1, and M-2 inhibited specific [ 3 H]NMS binding in the bladder in a concentration-dependent manner in vitro, and the binding activity of M-2 was roughly equipotent to that of propiverine, whereas M-1 was considerably less active than propiverine. Similar data on these agents were reported in human muscarinic receptor subtypes expressed in Chinese hamster ovary cells (Wuest et al., 2006) . Furthermore, oral administration of propiverine at pharmacologically relevant doses (24.8 -248 mol/kg) (Nomura et al., 1989; Oki et al., 2001 ) produced a significant increase in K d values for [ 3 H]NMS binding in the bladder. The significant increase in K d values was seen 3 h after the oral administration of this drug at the low dose (24.8 mol/kg) and 1 to 12 h at higher doses (74.3, 248 mol/kg).
Given that an increase in K d values for the radioligand in drugpretreated tissues in this type of assay usually indicates competition between the agent and radioligand for the same binding sites (Yamada et al., 1985 (Yamada et al., , 2003 Oki et al., 2004) , these results indicate that oral propiverine undergoes significant binding to bladder muscarinic receptors in rats. The dose of 74.3 mol/kg seemed to cause maximal blockade of the receptors as revealed by the plateau of K d enhancement for bladder [ 3 H]NMS binding ( Table 2 ). Note that propiverine exerted relatively selective and longer-lasting binding activity of muscarinic receptors in the bladder compared with the submaxillary gland, indicating bladder selectivity.
Propiverine is rapidly absorbed from the gastrointestinal tract, and its major pathway of elimination is hepatic metabolism (Yamamoto et al., 1989) . Plasma concentrations of M-1 and M-2 in rats after oral propiverine were higher than that of the unchanged form (Yamamoto et al., 1995) . Consistent with the observation, extremely (3.6 -5.9-fold) high concentrations of M-1 and M-2 were detected in the plasma of rats after the administration of propiverine at doses of 24.8 to 248 mol/kg (Fig. 3) . Both M-1 and M-2, as well as propiverine, reached a maximal level 1 h after treatment with propiverine, and high levels were maintained until at least 6 h at doses of 74.3 and 248 mol/kg propiverine. Thus, AUC values of total plasma concentration of M-1 and M-2 at these doses were 2.0 to 3.0 and 2.6 to 7.5 times greater, respectively, than the AUC value of propiverine. Furthermore, taking into account the difference in plasma protein binding of these compounds, much higher concentrations of unbound M-1 (C max , 12.5-14.9 times; AUC, 6.7-9.8 times) and M-2 (C max , 21.8 -36.1 times, AUC, 15.7-45.6 times) compared with the unchanged form were present in rat plasma.
Several approaches should be considered to estimate the contribution of pharmacologically active N-oxide metabolites in the actions of oral propiverine. One possible approach would be the estimation of proportion of muscarinic receptor binding activity by the plasma protein unbound fraction of propiverine and N-oxide metabolites. Therefore, estimates as unbound propiverine equivalents of M-1 and M-2 may allow us to elucidate the relationship between the total plasma concentration of propiverine and active metabolites and their bladder receptor binding activities. In other words, this parameter may help to quantitate the relative contribution of the metabolites to the unchanged form in the overall pharmacological action of oral propiverine. Thus, the plasma protein unbound C max and AUC were calculated by multiplying total concentrations (C max , AUC) by the plasma unbound ratios (0.11, 0.37, and 0.68, respectively) (Tsuda et al., 1991) of propiverine, M-1, and M-2. The sum of C max and AUC of plasma unbound propiverine equivalent in rats given propiverine at doses of 24.8 to 248 mol/kg was 66.1 to 509 nM and 194 to 4645 nM ⅐ h, respectively (Table 4) . Considering the in vitro K i value (0.30 M) of propiverine in displacing bladder [ 3 H]NMS binding (Table 1) , it is possible that propiverine at these doses produces a significant blockade of muscarinic receptors in the bladder in vivo. In fact, Nomura et al. (1989) have shown that the intravenous injection of 10.2 mol/kg propiverine significantly inhibited rhythmic bladder contractions in the cystometrogram of anesthetized rats. A similar attenuation of rhythmic bladder contractions was observed on the intravenous injection of M-1 and M-2.
A much higher concentration of M-2 than propiverine was detected in the plasma of rats 1 to 12 h after the oral administration of propiverine. The unbound M-2 in plasma comprised more than 90% of the sum of unbound propiverine equivalents in these rats (Table 4 ). M-2 displayed similar binding activity toward bladder muscarinic receptors as propiverine (Table 1) . Furthermore, M-2 inhibited markedly cholinergic contractions of isolated bladder strips Wuest et al., 2005) , and the intravenous injection of this metabolite inhibited potently maximal vesical pressure in the cystometrograms in rats (Nomura et al., 1989) . In connection with these observations, it was noteworthy that oral administration of propiverine exerted significantly potent binding of muscarinic receptors in the bladder than in the submaxillary gland (Table  2) . Therefore, the tissue concentrations of propiverine and its N-oxide metabolites were determined. Propiverine showed an extensive distribution from plasma to both the bladder and submaxillary gland, and the T/P values ranged from 5.8 to 8.0 in the bladder and from 17.8 to 24.4 in the submaxillary gland (Table 4) . These data were consistent with the large volume of distribution reported for propiverine (approximately 2 l/kg for humans; Haustein and Hüller, 1988) . Note that the tissue concentration and T/P value of M-2 compared with propiverine were much higher in the bladder and conversely much lower in the submaxillary gland. Taken together, the data indicate that M-2 may be largely responsible for the relatively selective and long-lasting occupation of bladder muscarinic receptors after the oral administration of propiverine.
The N-oxide metabolites of propiverine exhibited generally poor distribution to the bladder or submaxillary gland, except for the higher concentration of M-2 in the bladder. The specific distribution of M-2 to the bladder might be related to the higher excretion of the metabolite into urine. Up to 8 h after administration of propiverine, approximately 6% of dose was excreted into urine as M-2, which was 20-fold higher than that of parent drug or metabolite M-1 (Yamamoto et al., 1995) . Based on the urinary excretion reported, the average urinary concentration of M-2 is roughly expected to range from 50 to 200 M when rats received the 24.8-mol/kg dose, with the assumption that the daily urinary volume voided is in the range of 5 to 20 ml. In fact, we observed selective binding of bladder muscarinic receptors after the intravesical instillation of M-2 (30 M) into the rat bladder (Table  3) . Taken together, the data indicate that a part of M-2 was directly transferred from the urine to the bladder tissue by simple diffusion; thus, this metabolite could contribute largely to the long-lasting bladder selectivity in rats that received oral propiverine. Therefore, it can be presumed that the significant binding of muscarinic receptors in rat bladder by intravesical M-2 is pharmacologically relevant in terms of the functional blockade of these receptors.
There was a large divergence in pharmacological dosages of propiverine between humans and rats. In the majority of anticholinergic drugs, including propiverine, extensive metabolism is well known in animal species but not humans. The oral bioavailability of propiverine is approximately 50% in humans, but it is only 2% or less in rats (Yamamoto et al., 1995; Cyong et al., 2006) . The principal reason for the divergence in pharmacological dosages is the species difference in the metabolism of propiverine; therefore, the discussion FIG. 4 . Total plasma (A), bladder (B), and submaxillary gland (C) concentration-time profiles of propiverine (E), M-1 (Ⅺ), and M-2 (‚) after the oral administration of propiverine. Rats received propiverine (74.3 mol/ kg) orally and were then sacrificed. Blood samples, the bladder, and the submaxillary gland were taken. Each point represents the mean Ϯ S.E. for six rats.
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at ASPET Journals on October 29, 2017 dmd.aspetjournals.org related to the clinical significance should be based on the drug concentrations in plasma. Cyong et al. (2006) have previously reported that a single administration of propiverine to geriatric subjects at a therapeutic dose (20 mg; 50 mol) led to a C max of approximately 60 ng/ml (149 nM), and expected accumulation ratio was calculated to be 1.8 from its half-life time. Propiverine at concentrations of 100 nM to 10 M exhibited potent inhibition of acetylcholine-induced contractions of human detrusor smooth muscles through a blockade of muscarinic receptors (Wada et al., 1995) . Furthermore, the N-oxide metabolites were determined as major metabolites after a single administration of propiverine in humans Hüller et al., 1988; Wengler et al., 1988) , and the human serum protein binding of propiverine, M-1, and M-2 was 90, 60, and 20%, respectively (Meisel et al., 1997) , which was nearly equal to the values in rats. Furthermore, the urinary excretion of M-2 accounted for 4 to 5% of dose in humans, and the average urinary concentration of M-2 up to 12 h after the administration was estimated to be approximately 3 M (Cyong et al., 2006) . Therefore, it is plausible that concentrations of propiverine and N-oxide metabolites in rat plasma are closely associated with therapeutic ranges of these agents in patients with an overactive bladder and that M-2 contributes largely to the appearance of anticholinergic effects after the oral administration of propiverine in these patients. In conclusion, the present study has shown that M-2 may contribute greatly to the selective blockade of muscarinic receptors in the bladder after the oral administration of propiverine at pharmacologically relevant doses. BLQ, below the lower limit of quantification (LLOQ); N.A., not applicable. LLOQ for plasma: 5.4 nM (propiverine), 10.4 nM (M-1), and 5.9 nM (M-2); LLOQ for tissue samples was the product of the dilution factor (11.2-18.9 for bladder; 4.8 -7.8 for submaxillary gland) times the same value for plasma. 
